Sweden, Denmark halt Moderna's Covid-19 vaccine shot for younger people

The Swedish health authority Wednesday cited new data on the increased risk of heart inflammation as a reason for the pause for those aged 30 and under

Moderna
Denmark will stop giving the shot to those younger than 18
Charles Daly | Bloomberg
2 min read Last Updated : Oct 06 2021 | 10:44 PM IST
Sweden and Denmark decided to pause vaccinations with Moderna’s Covid-19 shot for younger people because of potential side effects.
 
The Swedish health authority Wednesday cited new data on the increased risk of heart inflammation as a reason for the pause for those aged 30 and under. Denmark will stop giving the shot to those younger than 18.
 
Moderna shares fell as much as 5 per cent in early trading in New York. The company didn’t immediately respond to a request for comment.  “We are monitoring the situation closely and are acting rapidly to ensure that Covid-19 vaccinations are constantly as safe as possible, while also providing protection,” said Anders Tegnell, Sweden’s chief epidemiologist.
 
Both countries recommended Pfizer’s and BioNTech SE’s rival vaccine as a replacement.
 
Sweden’s public health watchdog said a new preliminary analysis from the Nordic region indicates that the connection between vaccination and heart inflammation is clearest with the Moderna shot, especially after the second dose. The higher risk comes within four weeks of vaccination, and usually in the first two weeks, it said.
 
Those who have been vaccinated recently with a first or second dose of the Moderna vaccine shouldn’t worry, Tegnell said, as the risk is very small. Denmark’s National Board of Health indicated it hasn’t seen any differences in side effects between the two vaccines.
 
Both Moderna and Pfizer-BioNTech rely on messenger RNA technology to prompt an immune reaction. On Monday, the European Medicines Agency authorized the use of an extra dose of Moderna’s shot for those with a severely weakened immune system.
 
Last week, Slovenia temporarily halted another type of vaccine made by Johnson & Johnson after the death of a young woman who had received it.     


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineSwedenVaccination

Next Story